Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy
Susanna Myers, John Guy, Anthony L. Back, Juliana Pérez, Leslie Lazar Thorn, Bonnie A. Mcgregor
Psychedelic Medicine May 8, 2024 DOI: 10.1089/psymed.2023.0069 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Technical report Peer reviewed |
|---|---|
| Intervention | Psilocybin-assisted therapy |
| Topics | Psilocybin |
| Keywords | Therapeutic touch Clinical trial Psychotherapist Hallucinogen |
| Citations | 7 |
| Registration | NCT05847686 |
| Key points | After two unexpected touch-related experiences during the first three retreats, the initial practice guidelines for facilitator use of touch in group retreat-based psilocybin-assisted therapy were iterated into a new version specifying acceptable practices. |
Abstract
For a new clinical trial testing a group retreat-based format of psilocybin-assisted therapy, our research team created an initial set of practice guidelines that aimed to describe facilitator use of touch in a way that is ethical, supportive, and minimizes harm. In our first three retreats, however, we had two unexpected experiences with touch that led us to iterate our initial guidelines into a new version of guidelines. In this Technical Report, we describe our evolving guidelines specifying acceptable practices for facilitator use of touch to ensure a safe, supportive, and therapeutic participant experience. Our primary goal with these guidelines is to create a haptic experience during the psilocybin session that reinforces the participants' sense of safety and supports their own experience during the psilocybin session. Our secondary goal is to allow the facilitator team to notice and maintain therapeutic boundaries and to respond to participant experiences with empathy and openness in the context of those boundaries (Clinical Trials No: NCT05847686).